Leading pharmaceutical manufacturer, Aesica, has further enhanced its presence in the US with the appointment of a new business development director for the eastern US, Scott Silaika.
To coincide with Scott's appointment, Aesica has also opted to relocate its eastern office from New Jersey to New York.
Scott joins the company with over 14 years' experience in the pharmaceuticals industry including ten years within business development, sales and marketing. Prior to joining Aesica he was a key member of the contract services team at Ricerca Biosciences, where he supported the company's growth from 2004 onwards.
After graduating with a BSc in chemical engineering from Rensselaer Polytechnic Institute, Scott studied for an MBA from the State University of New York at Albany to hone his commercial skills.
Speaking of his appointment Scott says: "Aesica has a proven track record in providing primary and secondary contract manufacturing services to the highest possible standards and to be responsible for the company's continued growth across the eastern states is a real privilege. I was initially attracted to the company because its core capabilities of APIs and formulations are a winning combination and that Aesica can filter its APIs downstream through to packaging and final delivery is very rare, especially in terms of a Western offering."
He added: "It's Aesica's vision to become the world's leading supplier of APIs and formulated products and enhancing the company's presence in the US is a significant factor in ensuring this vision becomes a reality. As part of my remit I will be working closely with the business development director covering the western states and focusing on developing partnerships with large and emerging biotech and specialty pharma companies."
Aesica Pharmaceuticals has also recently announced that it has successfully acquired leading research and development company R5. R5 is Aesica's third UK acquisition since 2006 and will complement its existing formulations capability and enable it to significantly consolidate and enhance its portfolio of pharmaceutical and biotechnology clients.
Twitter